Researchers from Massachusetts Eye and Ear/Harvard Medical School recently released outcomes from a clinical trial surrounding the safety and efficacy of two treatments in patients with ocular graft-versus-host-disease (GVHD).
GVHD is a complication associated with allogeneic bone marrow transplants where the transplanted immune system's cells attack certain parts of the recipient's body, including the cornea and ocular surface. The clinical trial compared immunosuppressive therapy topical tacrolimus and steroid medication topical methylprednisolone, and found patients treated with tacrolimus experienced equal relief of ocular symptoms as those treated with methylprednisolone, with fewer negative serious side effects.
The trial findings were recently published in Ophthalmology.
Click here to read the full press release.
Source: Massachusetts Eye and Ear